Status:
UNKNOWN
Intravenous Terbutaline in Severe Status Asthmaticus
Lead Sponsor:
Wayne State University
Conditions:
Status Asthmaticus
Eligibility:
All Genders
2-18 years
Brief Summary
Terbutaline is a medication that is used to treat serious asthma attacks (status asthmaticus). The purpose of this study is to determine if terbutaline is effective and safe when given as a continuous...
Detailed Description
1. Background: Asthma remains a significant source of morbidity and mortality in children. In the United States, more than 11 million people reported having an asthma attack in the year 2000, and more...
Eligibility Criteria
Inclusion
- Children 2 to 18 years of age.
- Admission to the ICU with a diagnosis of status asthmaticus.
- The pediatric intensivist taking care of the patient has decided to initiate intravenous terbutaline therapy.
- An indwelling venous catheter or arterial catheter that was placed for routine ICU monitoring.
- Informed consent obtained from the patient's parents or legal guardian.
Exclusion
- Existing cardiovascular disease.
- History of bronchopulmonary dysplasia.
- Prior inclusion in this study.
- Known hypersensitivity to terbutaline, or prior adverse event associated with terbutaline.
- Terbutaline use within 48 hours of initiation of the study.
Key Trial Info
Start Date :
October 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2009
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00750568
Start Date
October 1 2007
End Date
August 1 2009
Last Update
September 10 2008
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Kosair Children's Hospital
Louisville, Kentucky, United States, 40202
2
Children's Hospital of Michigan
Detroit, Michigan, United States, 48201
3
Rainbow Babies and Childrens' Hospital
Cleveland, Ohio, United States, 44106